Crown Bioscience expands operations and re-brands UK site in Nottingham
The provider of oncology services will be re-named Crown Bioscience UK
Crown Bioscience, a global contract research organisation, will double the capacity of its PRECOS (Preclinical Oncology Services) facility in Nottingham, acquired in July 2013, and will rename the site Crown Bioscience UK.
In addition, Mike Prosser, Executive Director at Crown Bioscience has been appointed General Manager for Europe, responsible for leading the next stage of its UK development as well as Crown’s continued growth in Europe.
With these moves the company says it has completed the PRECOS merger, while the increased capacity represents a significant investment and long-term commitment to both its UK and European businesses.
The Nottingham facility, which is scheduled to be formally opened next month, will nearly double its operational footprint, encompassing both in vitro and in vivo capabilities. In parallel, it will become Crown's centre of excellence for models of hormone-related cancers (breast, prostate and ovarian), while continuing to provide a variety of oncology services to clients around the world.
These changes, in particular the opening of the new facility, will help us lead the way in the study of hormone-related cancers
Jean-Pierre Wery, President of Crown Bioscience, said: ‘Since the acquisition, Crown has been working to fully integrate the talents and resources of the company into the organisation. These changes, in particular the opening of the new facility, will help us lead the way in the study of hormone-related cancers, as well as strengthening our position in Europe.’
Prosser added: ‘Since the merger, investment in Crown UK has been key to the advancement of Crown Bioscience’s service portfolio, such as the development of an irradiation treatment platform for preclinical screening of drug-irradiation combination therapies. In 2015 we aim to continue our expansion of service provision, complimenting both the new therapeutic focus and expanded capacity of Crown UK, and in doing so leveraging and supplementing Crown’s arsenal of services and capabilities.’
Crown Bioscience is a key supplier of oncology and cardiovascular and metabolic disease research (CVMD) services with a global footprint, spanning three continents including North America, Europe and Asia Pacific. With the recent expansion of its research centre in North Carolina, the expansion of the UK facility is part of a wider strategy to reinforce and increase operations within Europe.